Fig. 1

Survival analyses after pelvic exenteration (PE) due to cervical cancer. Survival analysis of cervical cancer patient treated with PE due to cancer recurrence according to (a) initial FIGO stage IB, IIA, and IIB (n = 13) median overall survival (mOS) = 11.4 months, (interquartile range: 5.5-41.4) versus IIIA and IIIB (n = 10) mOS = 16.4 months (3.8-17.1) versus IVA and IVB (n = 9) mOS = 12.3 months (7.7–13.3), P = 0.70; (b) Type of PE: anterior (n = 6) mOS = 12.2 months (5.9-19.7) versus total (n = 22) mOS = 11.5 months (5-17.1) versus posterior (n = 4) 12.3 months (6.7-21.8), P = 0.88; (c) Histopathological type of the tumor: squamous cell carcinoma (n = 17) mOS = 20.5 months (4.9 to 33.1) versus adenocarcinoma mOS = 10.7 months (5.9 to 13.3), P = 0.01; (d) presence of vaginal fistula: absent (n = 28) mOS = 11.5 months (4.7-15.6) versus present (n = 4) mOS—not reached (16.055.6); (e) the need of repeated surgery within 30 days: reoperation within 30 days (n = 6) mOS = 4.5 months (3.2-10.7) versus no reoperation within 30 days (n = 26) mOS = 13.3 months (5.9-19.7), P = 0.02; (f) the presence of severe adverse events: severe adverse events reported (n = 11) mOS = 10.4 months (4.1-11.3) versus no severe adverse events (n = 21) mOS = 19.3 months (8.8-25.9), P = 0.03; (g) specimen margins status: positive margins (n = 5) mOS = 7.7 months (6.6-16.5) versus negative margins (n = 27) mOS = 12.3 months (4.7-16.6), P = 0.09; (h) lymph node metastases: absent (26) mOS = 12.3 (4.3-19.5), P = 0.55 versus present (6) mOS 11.5 months (6.2-13.1), P = 0.55; (i) time to recurrence: 0-12 months (n = 10) mOS = 13.3 months (7.7-19.3) versus 12-36 months (n = 14) mOS = 16.4 months (4.7-17.5) versus above 36 months (n = 8) mOS = 10.6 months (6.6-15.6), P = 0.31; (j) history of hysterectomy during initial treatment: hysterectomy performed (n = 3) mOS = 7.4 months (minimal and maximal value: 1.1 and 78.7) versus no hysterectomy (n = 29), mOS = 12.3 months (4.8-18.0), P = 0.78. Survival analysis of cervical cancer patients who underwent primary PE according to (k) presence of vaginal fistula: absent (n = 7) mOS = 12.9 months (8.2-16.4) versus present (n = 5) mOS = 22.5 months (9.4-62.9), P = 0.09; (l) histopathological type of cervical cancer: squamous cell carcinoma (n = 4) mOS = 47.6 months (8.0-70.9) versus adenocarcinoma (n = 8) mOS = 13.5 months (10.1-19.8); P = 0.33; (m) specimen margins status: positive margins (n = 2) mOS = 12.7 months (minimal and maximal value: 12.9 and 14.1) versus negative margins (n = 10) mOS = 13.5 months (8.2-30.5), P = 0.77; (n) lymph node metastases: absent (n = 8) mOS = 17.2 months (11.2-22.4) versus present (n = 4) mOS = 11.9 months (7.0-24.4); (o) severe adverse events: severe adverse events (n = 3) mOS = 19.1 months (minimal and maximal value: 7.4 and 86.7) versus no severe adverse events (n = 9), mOS = 12.7 months (9.3-18.5)